Achilles Therapeutics PLC
NASDAQ:ACHL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Achilles Therapeutics PLC
Income from Continuing Operations
Achilles Therapeutics PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Achilles Therapeutics PLC
NASDAQ:ACHL
|
Income from Continuing Operations
-$69.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£35.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Income from Continuing Operations
-$287.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£47.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Income from Continuing Operations
-£30.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Income from Continuing Operations
£7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Achilles Therapeutics PLC
Glance View
Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The firm's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.
See Also
What is Achilles Therapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-69.7m
USD
Based on the financial report for Dec 31, 2023, Achilles Therapeutics PLC's Income from Continuing Operations amounts to -69.7m USD.
What is Achilles Therapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-59%
Over the last year, the Income from Continuing Operations growth was 2%. The average annual Income from Continuing Operations growth rates for Achilles Therapeutics PLC have been -28% over the past three years , -59% over the past five years .
